- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02599597
Prevention of Depressive Relapse by Means of Physical Exercise and Lifestyle
3. März 2020 aktualisiert von: Olof Johansson, Lund University
Depression treatments including physical activity and sleep management has been shown to relieve depressive symptoms among participants suffering depressive episodes.
This study evaluates the potential of these methods as prevention of depressive relapse or recurrence
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
150
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Skåne
-
Malmö, Skåne, Schweden, 21431
- Vuxenpsykiatrimottagning allmänpsykiatri Fosievägen Malmö
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- A history of at least one episode of Major Depression.
- If medicating - Taking a stable (since one month) and therapeutic dosage of antidepressant medication
- Being able to read and write Swedish
- Having access to the internet
Exclusion Criteria:
- Fulfilling the criteria for Major depression
- Bipolar disorder
- Psychosis
- Substance abuse
- Suicidality
- Currently in psychotherapy
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Therapist-assisted iCBT
Internet-delivered cognitive behavioral therapy (iCBT), containing physical activity and sleep management for preventing depressive relapse.
Monthly depression screening with therapist feedback.
|
13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
|
|
Aktiver Komparator: Monthly screening with feedback
Monthly depression screening with therapist feedback.
|
Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
|
|
Kein Eingriff: Control
No intervention, follow-up along with all participants at 6 and 12-months.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Depressive relapse (change in diagnostic status, SCID-I)
Zeitfenster: Baseline - 12 months
|
Monthly screening via Montgomery-Asberg Depression Rating Scale - Self rated & Structured Clinical Interview for DSM IV
|
Baseline - 12 months
|
|
Change from baseline in depressive symptoms (MADRS-S)
Zeitfenster: Baseline - 6 months
|
Change in depressive symptoms will be measured by an internetbased version of the Montgomery-Asberg Depression Rating Scale - Self rated.
|
Baseline - 6 months
|
|
Change from baseline in depressive symptoms (MADRS-S)
Zeitfenster: Baseline - 12 months
|
Change in depressive symptoms will be measured by an internetbased version of the Montgomery-Asberg Depression Rating Scale - Self rated.
|
Baseline - 12 months
|
|
Change from baseline in depressive symptoms (MADRS-S)
Zeitfenster: Monthly, 0-12 months
|
Change in depressive symptoms will be measured by an internetbased version of the Montgomery-Asberg Depression Rating Scale - Self rated.
|
Monthly, 0-12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from baseline in health related quality of life (EQ-5D)
Zeitfenster: Baseline - 3 months
|
Health related quality of life will be measured by an internet based version of the EQ-5D.
|
Baseline - 3 months
|
|
Change from baseline in health related quality of life (EQ-5D)
Zeitfenster: Baseline - 6 months
|
Health related quality of life will be measured by an internet based version of the EQ-5D.
|
Baseline - 6 months
|
|
Change from baseline in health related quality of life (EQ-5D)
Zeitfenster: Baseline - 9 months
|
Health related quality of life will be measured by an internet based version of the EQ-5D.
|
Baseline - 9 months
|
|
Change from baseline in health related quality of life (EQ-5D)
Zeitfenster: Baseline - 12 months
|
Health related quality of life will be measured by an internet based version of the EQ-5D.
|
Baseline - 12 months
|
|
Change from baseline in Outcomes Questionnaire 45 (OQ-45)
Zeitfenster: Baseline - 3 months
|
The OQ-45 measures functioning in 3 domains: Symptom distress (heavily loaded for depression and anxiety), Interpersonal functioning, and Social Role.
It enables the clinician to assess functional level and change over time.
|
Baseline - 3 months
|
|
Change from baseline in Outcomes Questionnaire 45 (OQ-45)
Zeitfenster: Baseline - 6 months
|
The OQ-45 measures functioning in 3 domains: Symptom distress (heavily loaded for depression and anxiety), Interpersonal functioning, and Social Role.
It enables the clinician to assess functional level and change over time.
|
Baseline - 6 months
|
|
Change from baseline in Outcomes Questionnaire 45 (OQ-45)
Zeitfenster: Baseline - 9 months
|
The OQ-45 measures functioning in 3 domains: Symptom distress (heavily loaded for depression and anxiety), Interpersonal functioning, and Social Role.
It enables the clinician to assess functional level and change over time.
|
Baseline - 9 months
|
|
Change from baseline in Outcomes Questionnaire 45 (OQ-45)
Zeitfenster: Baseline - 12 months
|
The OQ-45 measures functioning in 3 domains: Symptom distress (heavily loaded for depression and anxiety), Interpersonal functioning, and Social Role.
It enables the clinician to assess functional level and change over time.
|
Baseline - 12 months
|
|
Change from baseline in the International Physical Activity Questionnaire (IPAQ)
Zeitfenster: Baseline - 3 months
|
The International Physical Activity Questionnaire is a measure of physical activity
|
Baseline - 3 months
|
|
Change from baseline in the International Physical Activity Questionnaire (IPAQ)
Zeitfenster: Baseline - 6 months
|
The International Physical Activity Questionnaire is a measure of physical activity
|
Baseline - 6 months
|
|
Change from baseline in the International Physical Activity Questionnaire (IPAQ)
Zeitfenster: Baseline - 9 months
|
The International Physical Activity Questionnaire is a measure of physical activity
|
Baseline - 9 months
|
|
Change from baseline in the International Physical Activity Questionnaire (IPAQ)
Zeitfenster: Baseline - 12 months
|
The International Physical Activity Questionnaire is a measure of physical activity
|
Baseline - 12 months
|
|
Morisky Medication Adherence Scale (MMAS-8)
Zeitfenster: Baseline - 3 months
|
Self-reported measure of medication adherence
|
Baseline - 3 months
|
|
Morisky Medication Adherence Scale (MMAS-8)
Zeitfenster: Baseline - 6 months
|
Self-reported measure of medication adherence
|
Baseline - 6 months
|
|
Morisky Medication Adherence Scale (MMAS-8)
Zeitfenster: Baseline - 9 months
|
Self-reported measure of medication adherence
|
Baseline - 9 months
|
|
Morisky Medication Adherence Scale (MMAS-8)
Zeitfenster: Baseline - 12 months
|
Self-reported measure of medication adherence
|
Baseline - 12 months
|
|
Insomnia Severity Index (ISI)
Zeitfenster: Baseline - 3 months
|
Insomnia issues
|
Baseline - 3 months
|
|
Insomnia Severity Index (ISI)
Zeitfenster: Baseline - 6 months
|
Insomnia issues
|
Baseline - 6 months
|
|
Insomnia Severity Index (ISI)
Zeitfenster: Baseline - 9 months
|
Insomnia issues
|
Baseline - 9 months
|
|
Insomnia Severity Index (ISI)
Zeitfenster: Baseline - 12 months
|
Insomnia issues
|
Baseline - 12 months
|
|
Alcohol Use Disorder Identification Test (AUDIT)
Zeitfenster: Baseline - 3 months
|
Baseline - 3 months
|
|
|
Alcohol Use Disorder Identification Test (AUDIT)
Zeitfenster: Baseline - 6 months
|
Baseline - 6 months
|
|
|
Alcohol Use Disorder Identification Test (AUDIT)
Zeitfenster: Baseline - 9 months
|
Baseline - 9 months
|
|
|
Alcohol Use Disorder Identification Test (AUDIT)
Zeitfenster: Baseline - 12 months
|
Baseline - 12 months
|
|
|
Time to depressive relapse
Zeitfenster: Baseline - 12 months
|
Time to depressive relapse is recorded as secondary outcome variable
|
Baseline - 12 months
|
|
Self reported treatment seeking
Zeitfenster: Baseline - 12 months
|
Treatment seeking among participants is recorded as secondary outcome variable
|
Baseline - 12 months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Lars-Gunnar Lundh, Professor, Lund University, Departement of psychology
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Februar 2016
Primärer Abschluss (Tatsächlich)
1. Dezember 2019
Studienabschluss (Tatsächlich)
1. Dezember 2019
Studienanmeldedaten
Zuerst eingereicht
5. November 2015
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
5. November 2015
Zuerst gepostet (Schätzen)
6. November 2015
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
4. März 2020
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
3. März 2020
Zuletzt verifiziert
1. März 2020
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- rel-prev
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .